Focus Partners Wealth
ACAD icon

Focus Partners Wealth’s Acadia Pharmaceuticals ACAD Stock Holding History

Focus Partners Wealth’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234K Sell
9,244
-162
-2% -$3.56K ﹤0.01% 2409
2026
Q1 		$209K Sell
9,406
-1,248
-12% -$29.8K ﹤0.01% 2398
2025
Q4 		$285K Sell
10,654
-9,219
-46% -$220K ﹤0.01% 2253
2025
Q3 		$2.11M Buy
+19,873
New +$470K ﹤0.01% 997

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Focus Partners Wealth's ACAD Position: Q2 2026 in Review

Focus Partners Wealth reduced its Acadia Pharmaceuticals (ACAD) stake by 1.7% in Q2 2026, selling an estimated $3.56K and leaving 9,244 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #2409.

Focus Partners Wealth first reported a position in ACAD in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.11M in Q3 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Focus Partners Wealth held 9,244 shares of Acadia Pharmaceuticals worth $234K as of Q2 2026.
  • Focus Partners Wealth sold 162 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.56K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2409 holding.
  • Focus Partners Wealth first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Focus Partners Wealth's Acadia Pharmaceuticals position peaked at $2.11M in Q3 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.